8-K: Omeros Announces Positive Results from Narsoplimab Expanded Access Program in TA-TMA, Bolstering BLA Resubmission

Omeros Corporation reports robust survival benefits for narsoplimab in treating TA-TMA patients within an expanded access program, supporting its upcoming BLA resubmission to the FDA.

Summary

• Omeros Corporation announced positive statistical analysis results from the expanded access program (EAP) for narsoplimab in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
• The analyses compared survival rates of narsoplimab-treated EAP patients to external control registry patients with similar risk profiles.
• The results showed that narsoplimab reduced the risk of mortality in high-risk TA-TMA patients by over 2-fold to approximately 3-fold.
• One-year survival rates for EAP patients who had failed previous treatments were significantly higher than historical rates for similar patients.
• These results will be included in the narsoplimab BLA resubmission to the FDA planned for later this quarter and in the MAA submission to European regulators targeted by mid-year.

Sentiment

Score: 8

Explanation: The document presents overwhelmingly positive clinical data, suggesting a significant advancement in the treatment of a life-threatening condition. The planned regulatory submissions indicate confidence in the drug's potential for approval.

Positives

• Narsoplimab shows a significant survival benefit in TA-TMA patients, even those who have failed other treatments.
• The results from the EAP are consistent with previous pivotal trial results, strengthening the case for narsoplimab's efficacy.
• No new safety signals of concern were observed during the EAP.
• The data supports the planned BLA resubmission to the FDA and MAA submission to European regulators.

Risks

• The BLA resubmission and MAA submission are subject to regulatory review and approval, which is not guaranteed.
• The FDA and EMA may not determine the registry used in the statistical analysis is sufficiently representative of TA-TMA patients.
• Unfavorable, unexpected or inconclusive results of statistical analyses relating to an external registry of TA-TMA patients could impact approval.
• Potential differences between the diagnostic criteria used in the pivotal trial and in the external registry could impact approval.

Future Outlook

Omeros plans to resubmit the BLA for narsoplimab to the FDA and submit the MAA to European regulators, with the goal of making the drug available to patients worldwide.

Management Comments

• Miguel-Angel Perales, MD, stated that there is a clear need for narsoplimab in the treatment of patients with TA-TMA.
• Michelle Schoettler, MD, stated that the EAP results of narsoplimab treatment for TA-TMA are exceptional.
• Gregory A. Demopulos, M.D., stated that the EAP-related and primary sensitivity analyses uniformly support the positive results of the primary endpoint.

Industry Context

TA-TMA is a serious complication of stem cell transplantation with no currently approved treatment, making narsoplimab a potentially valuable addition to the treatment landscape.

Comparison to Industry Standards

• Historical 1-year survival rates for patients who fail targeted TA-TMA therapy are less than 20 percent.
• Narsoplimab-treated patients in the EAP, including those who failed prior treatments, showed significantly higher 1-year survival rates (41% to 47%).
• Eculizumab is a complement inhibitor sometimes used off-label to treat TA-TMA, but narsoplimab targets a different part of the complement pathway (MASP-2) and has shown promise in patients who have failed eculizumab.

Stakeholder Impact

• Shareholders: Positive results could lead to increased stock value.
• Patients: Narsoplimab offers a potentially life-saving treatment option.
• Transplant physicians: Narsoplimab provides a new tool for managing TA-TMA.
• Omeros employees: Successful approval and commercialization would secure the company's future.

Next Steps

• Resubmission of the BLA to the FDA.
• Submission of the MAA to European regulators.
• Publication of manuscripts detailing the EAP-related and primary endpoint-related analyses in peer-reviewed journals.
• Preparation for the potential commercial launch of narsoplimab.

Key Dates

Keywords

narsoplimab, TA-TMA, Omeros, hematopoietic stem cell transplant, thrombotic microangiopathy, expanded access program, BLA, MAA, FDA, EMA, MASP-2, mortality, survival